- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00026624
Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects
The purpose of this study is to determine how safe it is to give patients a shot that has a mixture of a vaccine and dendritic cells (DCs), a special kind of immune cell, and how safe it is to give a shot of the vaccine alone.
Current HIV vaccines have not been strong enough to give good immune responses. Research has shown that the immune response to a vaccine delivered by DCs is greater than the response without DC delivery. A5130 is a study that seeks to give good delivery of the vaccine to important immune cells of the body.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Cytotoxic T-cell lymphocyte (CTL) responses are important in viral destruction and thereby in the protective immune response to viral infection. Current HIV vaccines do not consistently elicit strong CTL responses. The limited immune response of current HIV vaccines could be attributed, in addition to other causes, to failure of the vaccine to reach the appropriate cells to initiate a robust immune response. DCs particularly are effective in stimulating primary T-cell-dependent immunity. Antigen-bearing DCs are used as adjuvants for active immunotherapy in humans, particularly to increase host resistance to tumors and certain viral infections. A5130 is an exploratory, proof-of-concept study that seeks to ensure adequate delivery of the vaccine to important antigen-presenting cells.
Patients are randomized into 1 of 2 vaccination groups at entry. Group A: Patients receive an SC vaccination with DCs infected with ALVAC-HIV vCP1452. DC exposure to KLH occurs at Weeks 3 and 7. Leukopheresis occurs at entry.
Group B: Patients receive an SC vaccination with ALVAC-HIV vCP1452 without DCs. KLH injections are administered at Weeks 3 and 7.
Patients in both groups receive their vaccinations at Weeks 3, 7, and 15. This study consists of 4 steps but not all patients necessarily qualify to enter Step II, Step III, or Step IV.
Step I: vaccination phase. Step II: withdrawal of potent ART. Step III: optional discontinuation of ART. Step IV: reinitiation of ART. [AS PER AMENDMENT 04/10/02: Step V: follow-up period off potent ART.]
Studientyp
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital ACTG CRS
-
-
New York
-
New York, New York, Vereinigte Staaten, 10003
- Beth Israel Med. Ctr., ACTU
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Patients may be eligible for this study if they:
- Are HIV-infected.
- Took 3 or more anti-HIV drugs for 3 or more months before study entry.
- Have a viral load of 400 copies/ml or less for a period of 3 months before study start and within 30 days before study start.
- Have a CD4 count of 400 cells/mm3 or more for a period of 3 months before study start and within 30 days before study start.
- Have a CD4 count of 400 cells/mm3 or more at study screening.
- Have a viral load of 50 copies/ml or less at study screening.
- Are at least 18 years old.
- Agree not to become pregnant or to impregnate during the study and for 12 weeks after the study, if able to have children.
Exclusion Criteria
Patients may not be eligible for this study if they:
- Have a short-term but intense infection or serious illness within 14 days before study start and have not completed therapy or are not clinically stable on therapy.
- Have viral load values greater than 400 copies/ml within 3 months before study start.
- Have CD4 counts less than 400 cells/mm3 within 3 months before study start.
- Have close contact with canaries through work (e.g., breeding farms, bird shops). Does not apply to pet canaries.
- Are allergic to eggs or neomycin. Have a history of serious allergic reactions including allergy-induced asthma.
- Are sensitive or allergic to study drugs.
- Use drugs or alcohol in a way that would interfere with the patients' ability to follow the study requirements.
- Have become HIV-positive within 1 year before study start.
- Are pregnant or breast-feeding.
- Have had lymph node irradiation.
- Have had any HIV vaccine.
- Have used hydroxyurea within 45 days of study start.
- Have received drugs that affect the immune system, such as corticosteriods, within 30 days before study start.
- Are allergic to shellfish. (This study has been changed to make shellfish allergy an exclusion criterion and to remove abacavir use as an exclusion criterion.)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Maskierung: Keine (Offenes Etikett)
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Jeffrey Jacobson
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- Physiologische Wirkungen von Arzneimitteln
- Immunologische Faktoren
- Adjuvantien, Immunologische
- Keyhole-Limpet-Hämocyanin
Andere Studien-ID-Nummern
- A5130
- 10080 (DAIDS ES Registry Number)
- AACTG A5130
- ACTG A5130
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur ALVAC(2)120(B,MN)GNP (vCP1452)
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-Infektionen | HIV SeronegativitätBrasilien, Peru, Haiti, Trinidad und Tobago
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-Infektionen | HIV SeronegativitätVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-Infektionen | HIV SeronegativitätVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...New York Presbyterian HospitalAbgeschlossenHIV-InfektionenVereinigte Staaten